IMPORTANCE Antibiotic exposures in early life may affect weight by altering gut microbiota, potentially increasing the likelihood of childhood obesity.
Introduction
New Zealand has the third highest prevalence of obesity among Organisation for Economic Co-operation and Development countries. 1 Pediatric obesity is associated with development of cardiovascular risk factors in later life, such as type 2 diabetes, hypertension, dyslipidemia, and metabolic syndrome. 2 Antibiotic exposures in early life can change the bacterial composition of the intestine (microbiome), potentially increasing the risk of childhood obesity. 3 Antibiotics affect weight by altering gut microbiota, which moderates the harvesting, storage, and expenditure of energy from dietary sources. 3 Several child cohort studies have reported associations of antibiotic exposure with higher body mass index (BMI), 4, 5 overweight, [5] [6] [7] or obesity. [8] [9] [10] However, previous studies addressing this issue have limitations, including parent-reported antibiotic exposure, 5,6,10 parent-reported weight and height, 11 lack of height data, 12 use of covariates measured at the same point as BMI, 7 and restricting antibiotic exposure to children with specific diagnoses. 13, 14 Furthermore, previous studies were not designed to incorporate antibiotic exposure during pregnancy.
The overall aim of the present analysis was to examine the association between antibiotic exposure by age 48 months and body mass at age 54 months, using a cohort that has established linkage to antibiotic prescribing data and collected reliably measured anthropometric data.
Specifically, this research evaluates whether the number, timing (age), and type of antibiotic exposures are associated with a higher body mass and an increased likelihood of overweight and obesity. This work incorporates antibiotic exposure during pregnancy.
Methods

Data Source and Sample
This analysis was undertaken during 2017 to 2018 within a prospective cohort study in New Zealand (the Growing Up in New Zealand study) in which 6853 children born during 2009 to 2010 were enrolled antenatally. Birth characteristics of the cohort aligned with the national birth cohort from 2007 to 2010. The Ministry of Health Northern Y Regional Ethics Committee approved the study, and enrolled parents gave written informed consent. The Data Access Committee that was established for this cohort study approved access to data sets used in this analysis. A detailed profile of the cohort is described elsewhere. 15 Reporting of this analysis followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Parents completed computer-assisted personal interviews antenatally and when their children were aged approximately 9, 24, and 54 months. Of the 6156 children who participated in the 54-month follow-up, 5734 of 6156 (93%) had both weight and height measured in duplicate by trained interviewers using standard protocols and identical sets of calibrated equipment. Where duplicate measurements of height differed by more than 1 cm or weight by more than 500 g, a third measurement was taken. The study obtained community pharmacy antibiotic dispensing data from the New Zealand Pharmaceutical Collection database for the 5666 children whose parents consented to external data linkage in addition to their mothers' antibiotic dispensing data during pregnancy. Systemic use of antibacterial agents is via prescription only in New Zealand.
Antenatal, perinatal, and 24-month follow-up questionnaires were reviewed for availability of data to assess factors that could affect body mass. To exclude children with antenatal conditions affecting growth, the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes Q00 to Q99 were used to determine the presence of congenital anomalies.
The Figure shows the exclusion procedure used to select the study sample. This included 5406 singletons with prescription data and 54-month weight and height measurements and excluded 278 singletons who met 1 or more of the following criteria: gestational age less than 28 weeks or missing
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Association of Repeated Antibiotic Exposure With Body Mass at Age 4.5 Years data, birth weight data missing, or congenital anomalies present. This resulted in an analytic sample of 5128 children.
Measures of Body Mass
Two measures of body mass were derived using the child's weight and height measurements, age when measured, and sex. We derived BMI-for-age z scores (zBMI) using World Health Organization child growth chart standards. 16 Using the child's BMI (calculated as weight in kilograms divided by height in meters squared), age, and sex, the second measure was derived using the International Obesity Task Force (IOTF) cutoff points for overweight and obesity defined to pass through adult BMI values of 25 and 30, respectively. 17 The IOTF definition is less arbitrary and was developed to encourage direct comparisons of childhood obesity trends worldwide. The IOTF BMI variable categorizes children into 3 groups (normal or underweight, overweight, and obese).
Measures of Antibiotic Exposure
Variables measuring children's exposure to any antibiotics and to 4 types (penicillins, macrolides, cephalosporins, and co-trimoxazole) between birth and age 48 months were derived to quantify the following: any exposure (yes or no), number of dispensings, age at first exposure, and timing (age) of exposures. Maternal exposure to antibiotics during pregnancy was quantified as any exposure (yes or no) and number of dispensings between the estimated date of conception and child's date of birth.
Statistical Analysis
The unadjusted analysis of 5128 participants examined associations of measures of antibiotic exposure with continuous variables (zBMI and potential confounders) using generalized linear models and categorical variables (IOTF BMI and potential confounders) using χ 2 tests. In addition, unadjusted associations between any exposure to antibiotics (yes or no) and potential confounders were examined. Continuous variables were summarized using their means and standard deviations, and categorical variables were summarized using counts and percentages. Owing to study ethical requirements, "<10" denotes categories with fewer than 10 participants.
The multivariable analysis sample comprised 4398 children with complete (nonmissing) data for factors significantly associated (P < .05) with body mass and excluded variables with missing data for at least 10% of the analytic sample (maternal relationship status, smoking in pregnancy, and selfreported prepregnancy BMI). Missing data for self-reported prepregnancy BMI were due to a higher proportion of missing values for self-reported height (9%) than weight (4%). Therefore, selfreported weight was added to the multivariable analysis and, because it had missing values for 3% of the multivariable sample (129 of 4398), the analysis commenced with multiple imputation (25 replicates) that included the following variables: log value of self-reported weight (assumed to be missing at random), any antibiotic exposure, and factors significantly associated with body mass in the unadjusted analysis.
Using the imputed data set, multivariable generalized linear models were used to assess adjusted associations between antibiotic exposure variables and zBMI (continuous outcome); results were summarized using pooled adjusted means and their standard errors. For the IOTF BMI variable (nominal outcome), multinomial logistic regression was used to determine whether antibiotic exposure was associated with increased likelihood of overweight or obesity with normal and underweight children as the comparison group; results were summarized using pooled adjusted odds ratios (aORs) and their 95% confidence intervals. Multivariable models adjusted for the child's sex; birth weight; delivery mode; birth season; birth order; antireflux medication dispensed by age 48 months; sleep duration at age 24 months; time spent (last weekday) watching television, DVDs, or videos at age 24 months; exclusive breastfeeding duration; and dietary intake at age 24 months. The models also adjusted for maternal age, self-identified ethnicity, education, socioeconomic deprivation, 18 self-reported prepregnancy weight (log scale), antibiotic exposure in pregnancy, and alcohol use in pregnancy. Statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc). A 2-tailed P < .05 was considered statistically significant.
Results
Study Sample
The 
Selection of the Study Population
Of 6669 singletons, 5521 (83%) had maternal consent for child prescription data ( Figure) . Compared with singletons whose mothers provided this consent, singletons lacking consent had lower birth Among singletons whose mothers provided consent for child prescription data linkage, 98% (5405 of 5520) had both weight and height measured at the 54-month follow-up ( Figure) . Singletons with weight and height data did not differ significantly from those without these data with respect to birth weight, gestational age, delivery mode, and maternal age, education, ethnicity, and socioeconomic deprivation (eTable 2 in the Supplement). However, singletons lacking weight and height data were disproportionally male (71 [62%] vs 2791 [52%]). 
Factors Associated With Any Antibiotic Exposure by Age 48 Months
Of 5128 children in the analytic sample, 4886 (95%) were exposed to antibiotics by age 48 months.
Compared with the unexposed, a larger proportion of children in the exposed group were male (2523 
Unadjusted Associations of Antibiotic Exposure With Body Mass
As shown in Table 1, children exposed to antibiotics had a higher zBMI (mean [SD], 0.95 [1.20] vs (Table 1 ). Significant trends were present for the increase in proportion of children with overweight (χ 2 P < .001 for trend) or obesity (χ 2 P < .001 for trend) as the number of dispensings increased and age of first exposure decreased.
Children exposed to and with increasing dispensings for penicillins, macrolides, cephalosporins, or co-trimoxazole had higher mean zBMI compared with no type-specific exposure (eTable 7 and eTable 8 in the Supplement). Associations between age at first exposure and increased zBMI were present in children whose exposure to penicillin began at age 0 to 6 months and greater than 6 to 12 months. For macrolides, cephalosporins, and co-trimoxazole, children whose exposure began in the first year of life had a significantly higher zBMI, but this association was also apparent for exposures initiated up to age 36 months.
Unadjusted Associations of Perinatal, Environmental, and Social Factors With Body Mass
Several factors were associated with both a higher mean zBMI and likelihood of overweight or obesity ( 
Association Between Repeated Antibiotic Exposure and Body Mass
In multivariable analyses, antibiotic exposure was associated with both measures of body mass ( 
Association Between Timing (Age) of Antibiotic Exposure and Body Mass
The multivariable analyses showed that antibiotic exposure beginning in the first year of life was Table 4 ). In addition, receiving 2 or more dispensings of macrolides was associated with obesity (aOR, 1.61; 95% CI, 1.18-2.21), as was receiving 2 or more dispensings of co-trimoxazole (aOR, 1.52; 95% CI, 1.13-2.04). Neither was associated with overweight. Exposure to cephalosporins was not associated with body mass in the multivariable analysis.
Discussion
In this prospective cohort study that examined the association between antibiotic exposure by age 48 months and body mass at age 54 months, repeated exposure to antibiotics was associated with higher mean zBMI and greater likelihood of obesity. Antibiotic exposure during pregnancy was also associated with an increased zBMI. In addition, children whose antibiotic exposure began in the first
year of life had a higher zBMI than those who were unexposed, whereas children whose antibiotic exposure commenced after the first year of life did not differ significantly from those who were unexposed. This would be expected, as children whose exposure commences earlier in life tend to have more antibiotic dispensings over time than those whose initial exposure is delayed.
To our knowledge, this is the first study to incorporate antibiotic exposure during pregnancy in examining the association between antibiotic exposures in early childhood and body mass. Antibiotic exposure in pregnancy was associated with higher BMI in children whose mothers had 2 or more antibiotic prescriptions compared with no exposure (adjusted mean zBMI difference of 0.12), but there was no association with overweight or obesity (aOR, 1.65; 95% CI, 1.00-2.71; P = .05). Previous cohort studies 19, 20 examining prenatal antibiotic exposure and childhood obesity did not include the children's own antibiotic exposure. Mor et al 20 reported a higher adjusted prevalence ratio for overweight and obesity in Danish children aged 7 to 16 years whose mothers had 3 or more antibiotic prescriptions during pregnancy compared with the unexposed. In a US study 19 of 436 mother-child dyads, children whose mothers self-reported antibiotic use in the second and third trimesters had higher zBMI and an increased risk of obesity at 7 years. Findings from the present study suggest that antibiotic exposure both before and after birth are associated with body mass in early childhood. Consistent with the present study, findings from cohort studies 4, 9 show that children whose antibiotic prescriptions are initiated during the first 6 or 12 months of life have higher BMI on average.
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These findings are consistent with the notion that gut microbiota are susceptible to disruptions, particularly during infancy when the founding microbiota infants acquire at birth have not developed into a stable microbial community. 3 Such disruptions can occur via infant exposure to antibiotics and possibly via maternal antibiotic exposure, as infants acquire part of their early life microbiota from their mother. 3 Several cohort studies 4,7-9 have reported findings comparable to the present study with regard to repeated antibiotic exposure and body mass. A retrospective cohort study in the United Kingdom 8
found an increasing likelihood of obesity at age 4 years with 3 or more antibiotic exposures by age 2 years. Among children attending a primary care practice network in the United States, those with 4 or more antibiotic prescriptions at age 0 to 23 months had an increased risk of obesity at age 24 to 59 months. 9 In a Canadian birth cohort, 7 children with antibiotic exposure in the first year of life were 1.7 and 2.6 times more likely to be overweight at ages 9 and 12 years, respectively. A population-based study 4 in Finland reported higher zBMI at age 24 months and older in children exposed to antibiotics when aged younger than 24 months and a linear trend in zBMI with increasing antibiotic prescriptions.
Other cohort studies have reported either no association between antibiotic exposure and body mass or an association of unlikely clinical significance. A cohort study in the United States 14 that used health care data reported a modest association of antibiotic exposure at ages younger than 2 years with zBMI and overweight or obesity prevalence at age 5 years; the authors concluded that the clinical significance of a 0.02 to 0.07 increase in BMI z-score at age 5 years is likely negligible for individual patients. However, misclassification of antibiotic exposure is possible, as the study used electronic records (as opposed to prescription dispensing or claims) only within, but not outside, Some cohort studies 4, 9, 21, 22 have reported findings comparable to the present study with regard to exposure to specific antibiotic types and BMI. Differences by antibiotic type may be due to their different modes of action on bacteria. For instance, penicillins and cephalosporins target the bacterial cell wall by interrupting cell wall synthesis during cell division, macrolides target the ribosome by interfering with protein synthesis, and sulphonamides act by inhibiting folic acid synthesis. 21 Bailey et al 9 found a greater risk for obesity at age 24 to 59 months in children who at ages 0 to 23 months had 4 or more treatment episodes with broad-spectrum antibiotics (defined as systemic antibiotics excluding penicillin and amoxicillin), but not for narrow-spectrum antibiotics (penicillin and amoxicillin). Saari et al 4 reported that boys (but not girls) with 2 or more macrolide prescriptions by age 24 months were more likely to be overweight at age 24 months or older and have higher zBMI on average. Comparably, Korpela et al 22 found an association between exposure to macrolide-type antibiotics during the previous 2 years and BMI in children aged 2 to 7 years.
Furthermore, intestinal microbiota in the macrolide-exposed children showed changes previously associated with increased BMI, adiposity, obesity, or metabolic diseases in children or adults. 22 
Strengths and Limitations
This study has several strengths. It used dispensed prescription data to determine children's antibiotic exposure at the same age to allow an equal opportunity for exposure, as well as maternal exposure during pregnancy; however, the national pharmaceutical database does not include medications prescribed in hospitals. In addition, this study examined the number, timing (age), and type (penicillins, macrolides, cephalosporins, co-trimoxazole) of antibiotic exposure. The study outcome measures were based on reliably measured BMI data in a large and ethnically diverse sample and the analyses accounted for many factors associated with body mass.
This study also has some limitations. First, mothers who did not consent to prescription data linkage and whose children had incomplete data in the multivariable analysis were disproportionally of non-European ethnicities and lived in more deprived areas. As these groups have higher obesity prevalence rates in New Zealand, this limitation may have underestimated the magnitude of the association between antibiotic exposure and body mass. Second, maternal household income was unreported by 24% of enrolled mothers (1613 of 6822); hence, it was not used in the analysis. Third, maternal BMI and gestational weight gain data could not be obtained via maternal health records.
Fourth, prepregnancy weight and height were collected via self-report. A study on the validity of selfreported height, weight, and BMI by the US Centers for Disease Control and Prevention 23 showed a reporting bias in these data whereby women tended to underreport their weight and overreport their height, resulting in an underestimation of BMI; underreporting of weight increased as BMI and age increased.
Conclusions
This study found that repeated exposure to antibiotics by age 4 years was associated with significantly higher BMI and greater likelihood of obesity at age 4.5 years. In addition, repeated antibiotic exposure in pregnancy was associated with higher BMI in young children. Timing of antibiotic exposure was also associated with BMI; compared with those who were unexposed, children whose exposure began during the first year of life had higher mean zBMI , whereas those whose exposure began after the first year of life did not. The study findings suggest that repeated antibiotic exposure may be a potentially modifiable risk factor for childhood obesity. Future research could examine whether interventions that seek to reduce unnecessary prescribing of antibiotics to children in primary care (for example, clinical rules that identify children at low risk of needing antibiotics 24 ) can also reduce the prevalence of childhood obesity. 
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